← Eichor
Condition: Overweight Or Obese Adults Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Overweight Or Obese Adults

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Ad
Phase 2 · 2 location(s) · Golo · NCT05844644A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Phase 3 · 173 location(s) · Eli Lilly and Company · NCT07392190A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in A
Phase 1 · 1 location(s) · Novo Nordisk A/S · NCT07597018A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Phase 1/Phase 2 · 6 location(s) · Wave Life Sciences USA, Inc. · NCT06842186Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being
NA · 1 location(s) · Waianae Coast Comprehensive Health Center · NCT07536256A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Phase 3 · 25 location(s) · Pfizer · NCT07595549The 6-minute Pegboard and Ring Test in Overweight and Obese Individuals
Phase N/A · 1 location(s) · Kirsehir Ahi Evran Universitesi · NCT06742112A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepati
NA · 1 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT07364175A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Phase 1 · 1 location(s) · Shanghai World Leader Pharmaceutical Co., Ltd. · NCT07465965Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
Phase 1 · 2 location(s) · Alveus Therapeutics, Inc. · NCT07399678A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overw
Phase 2 · 42 location(s) · Eli Lilly and Company · NCT07215559Thread Embedding Acupuncture Therapy for Weight Loss
NA · 1 location(s) · Beijing Hospital of Traditional Chinese Medicine · NCT06653530A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity
Phase 1 · 2 location(s) · Hoffmann-La Roche · NCT07499050A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Phase 1/Phase 2 · 1 location(s) · Pfizer · NCT06924320Screening for Malnutrition in Obese Patients
Phase N/A · 3 location(s) · HAN University of Applied Sciences · NCT06626360Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Ca
Phase 3 · 44 location(s) · Amgen · NCT07575399Effects of Protein Supplementation on Brain Function
NA · 1 location(s) · Maastricht University Medical Center · NCT07057245Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Phase 3 · 161 location(s) · Eli Lilly and Company · NCT07353931A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
Phase 2/Phase 3 · 4 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT07284511Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressur
Phase 3 · 54 location(s) · Amgen · NCT07226765Pistachio Snacking and Metabolic Flexibility
NA · 1 location(s) · University of South Carolina · NCT07340125A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesit
Phase 2 · 54 location(s) · Eli Lilly and Company · NCT06143956A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Phase 4 · 21 location(s) · Eli Lilly and Company · NCT07438444A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
Phase 1 · 1 location(s) · Syntis Bio · NCT07307274Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
Phase 1 · 1 location(s) · Shanghai Xitaili Biomedicine Technology co., Ltd. · NCT07205432A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Pa
Phase 4 · 40 location(s) · Eli Lilly and Company · NCT06857942Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
NA · 1 location(s) · Kazakh Academy of Nutrition · NCT07728669A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Phase 3 · 162 location(s) · Eli Lilly and Company · NCT07321886A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa
Phase 1 · 3 location(s) · AstraZeneca · NCT07511205A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psori
Phase 4 · 55 location(s) · Eli Lilly and Company · NCT06864026
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.